The total costs of treatment were Bfr 1,317,727 for the placebo, Bfr 1,312,015 for the ASA and Bfr 1,326,526 for the ASA-DP.
The ASA strategy was less costly than the placebo (Bfr -5,712).
The combination ASA-DP was more costly both with respect to the placebo (Bfr 8,799) and ASA only (Bfr 14,511).
Costs were discounted at 3% per year.